XyloCor hires Reinhardt as CMO to lead gene therapy programs

Reinhardt and XyloCor CEO Gianchetti both worked at GSK earlier in the decade. (Pixabay / rawpixel)

XyloCor Therapeutics has named Rickey Reinhardt as CMO. Reinhardt, who helped GlaxoSmithKline get a gene therapy to market, joins XyloCor to take genetic treatments for cardiovascular diseases through clinical development.  

Philadelphia-based XyloCor set itself up to move a gene therapy treatment for treatment-resistant angina into clinical development late last year when it raised $17 million in a series A co-led by LSP and Sofinnova Partners. The gene therapy, XC001, is designed to improve blood supply by stimulating the formation of coronary blood vessels.

Al Gianchetti, who spent more than 20 years at GSK across two stints, is leading XyloCor and has turned to one of his former colleagues for support. Gianchetti and Reinhardt crossed paths at GSK earlier in the decade. During that time, Reinhardt helped to get the ex-vivo gene therapy Strimvelis to market.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Reinhardt left GSK in 2016 to take up the position of VP, clinical R&D at Regenxbio. That position put Reinhardt in charge of translational medicine and clinical development for Regenxbio’s early phase gene therapy programs targeting rare neurodegenerative pediatric disorders and an eye indication.

After two years at Regenxbio, Reinhardt moved on, taking up the CMO role at Comet Therapeutics. Comet is working to treat inborn errors of metabolism.

XyloCor is betting that the experience Reinhardt gained at those companies will benefit its pipeline as it moves XC001 into phase 1 and progresses another cardiac candidate toward the clinic. 

“His proven success in driving drug development from discovery through phase 4 in areas such as oncology, cardiometabolics and rare diseases, including several clinical-stage gene therapy programs, will be a tremendous asset to our company,” Gianchetti said in a statement. 

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.